BGB324 (bemcentinib)

Source: Immuno-Oncology News, May 2018

BGB324 (bemcentinib), from BerGenBio, is being developed as a treatment for triple-negative breast cancer, non-small cell lung cancer (NSCLC)acute myeloid leukemiamyelodysplastic syndrome, and metastatic melanoma.

How BGB324 works

BGB324 is an orally administered AXL inhibitor. AXL is a tyrosine kinase receptor, a protein found on the surfaces of some cells, particularly those of the immune system, that fight tumors. It is found at high levels on immune cells in the vicinity of some tumors. AXL strongly suppresses the immune system when activated. It is also present on the surfaces of some tumor cells, making them resistant to immune attacks. BGB324 is designed to inhibit AXL and allow the body’s own immune system to kill tumor cells.
read the original full article